Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23495404 | 0.88 | RAPGEF4 (0.41) | RAPGEF4 | |
| SCHEMBL27129828 | 0.86 | RAPGEF4 (0.31) | RAPGEF4 | |
| SCHEMBL7494959 | 0.83 | TSHR (0.30) | — | |
| SCHEMBL1435114 | 0.78 | KEAP1 (0.38) | AGBL2 | |
| SCHEMBL893003 | 0.78 | ALDH1A1 (0.41) | — | |
| SCHEMBL585059 | 0.78 | HRH3 (0.40) | RAPGEF4 | |
| SCHEMBL21749452 | 0.76 | HTR1D (0.41) | — | |
| SCHEMBL17648045 | 0.76 | HRH3 (0.39) | RAPGEF4 | |
| SCHEMBL16670956 | 0.76 | TRPA1 (0.33) | — | |
| SCHEMBL16693754 | 0.76 | RAPGEF4 (0.32) | RAPGEF4PTGS1PTGS2AGBL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025058459-A1 | NOVEL IMIDAZOPYRIDINE-BASED COMPOUND AND COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING, ALLEVIATING, OR TREATING GASTROINTESTINAL INFLAMMATORY DISEASES OR GASTRIC ACID-RELATED DISEASES | (주)휴온스 | 2025-03-20 | — | — | WO | disclosed |
| US-20240002344-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | FIBROGEN, INC. | 2024-01-04 | — | — | US | disclosed |
| EP-4204400-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | Fibrogen, Inc. (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-116348450-A | Compounds, compositions and methods for histone lysine demethylase inhibition | 菲布罗根有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-115667237-A | Novel heterocyclic compounds as BET inhibitors | 成都苑东生物制药股份有限公司 | 2023-01-31 | — | — | CN | disclosed |
| WO-2022047230-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | FIBROGEN, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022012456-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD. (CN) | 2022-01-20 | — | — | WO | disclosed |
| EP-3481827-B1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, METHODS FOR PREPARING THE SAME AND USE THEREOF | JEIL PHARMACEUTICAL CO LTD (KR) | 2021-11-03 | — | — | EP | disclosed |
| CN-109415362-B | Imidazo [1,2-a ] pyridine derivatives, process for their preparation and their use | 第一药品株式会社 | 2021-07-30 | — | — | CN | disclosed |
| US-10696671-B2 | Imidazo[1,2-A]pyridine derivatives, methods for preparing the same and use thereof | JEIL PHARMACEUTICAL CO., LTD. (KR) | 2020-06-30 | — | — | US | disclosed |
| US-6265415-B1 | ANTIULCER AGENT | ASTRAZENECA AB (SE) | 2001-07-24 | — | — | US | disclosed |
| EP-1105391-A2 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2001-06-13 | — | — | EP | disclosed |
| EP-1073657-A1 | IMIDAZO PYRIDINE DERIVATIVES WHICH INHIBIT GASTRIC ACID SECRETION | AstraZeneca AB (SE) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999055706-A9 | IMIDAZO PYRIDINE DERIVATIVES WHICH INHIBIT GASTRIC ACID SECRETION | ASTRA AB (SE) | 2000-03-16 | — | — | WO | disclosed |
| WO-2000011000-A2 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2000-03-02 | — | — | WO | disclosed |
| EP-0971920-A1 | COMPOUNDS FOR INHIBITION OF GASTRIC ACID SECRETION | Astra Aktiebolag (SE) | 2000-01-19 | — | — | EP | disclosed |
| WO-1999055706-A1 | IMIDAZO PYRIDINE DERIVATIVES WHICH INHIBIT GASTRIC ACID SECRETION | ASTRAZENECA AB (SE) | 1999-11-04 | — | — | WO | disclosed |
| EP-0906288-A1 | NEW COMPOUNDS | Astra Aktiebolag (SE) | 1999-04-07 | — | — | EP | disclosed |
| WO-1998037080-A1 | COMPOUNDS FOR INHIBITION OF GASTRIC ACID SECRETION | ASTRA AKTIEBOLAG (SE) | 1998-08-27 | — | — | WO | disclosed |
| WO-1997047603-A1 | NEW COMPOUNDS | ASTRA AKTIEBOLAG (SE) | 1997-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696671-B2 | Imidazo[1,2-A]pyridine derivatives, methods for preparing the same and use thereof | HRH2, GIPR, HRH4 | RAPGEF4 440/4885PTGS1 28/4885PTGS2 90/4885 |
| US-20240002344-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | KDM5C, KDM5B, KDM5A | RAPGEF4 2692/4885PTGS1 2879/4885PTGS2 2971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.